{"name":"Tyra Biosciences","slug":"tyra","ticker":"TYRA","exchange":"NASDAQ","domain":"tyrabio.com","description":"Tyra Biosciences is a precision oncology company focused on developing targeted therapies for cancer treatment. The company's pipeline includes several promising candidates, including TYRA-100 and TYRA-200. With a strong focus on precision medicine, Tyra Biosciences aims to improve patient outcomes and quality of life. As a relatively new player in the biotech industry, Tyra Biosciences has significant growth potential.","hq":"San Diego, CA","founded":0,"employees":"","ceo":"Todd Harris","sector":"Precision Oncology / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$1.3B","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":102928000,"netIncome":-119947000,"cash":77387000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"TYRA-100 patent cliff ($0.0B at risk)","drug":"TYRA-100","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"TYRA-200 patent cliff ($0.0B at risk)","drug":"TYRA-200","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"TYRA-100 Receives FDA Fast Track Designation for Treatment of Advanced Solid Tumors","summary":"The FDA granted Fast Track designation to TYRA-100 for the treatment of advanced solid tumors, allowing for expedited review and potential accelerated approval.","drugName":"TYRA-100","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Tyra Biosciences Reports Third Quarter 2023 Financial Results","summary":"The company reported a net loss of $23.4 million for the third quarter of 2023, with research and development expenses increasing to $17.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-09-18","type":"deal","headline":"Tyra Biosciences Enters into Collaboration Agreement with Merck KGaA","summary":"The company entered into a collaboration agreement with Merck KGaA to develop and commercialize TYRA-100 in certain territories.","drugName":"TYRA-100","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxQYUxlMXk3YW1LMGNlOEZIWkNMSXEtUnVrSnVzNkF1SFY5RzhSTGRtTTE5bGFBQzZCX09kTUVyRF9oS3p0ZjRNaTFJUU9qclJpeFlXU1VNbUxfRjF2bldqN0k0TTZ1TVAyTndOV2xvMFZpZ0tTODRrRGJkUk94SnpCY2cwTjlZMlpZb3p3bVNJR2o4aE9PTE9kVGcyS1dNU25CTjNOSVFtODRHOXFJSTRPLTNRdW03MFdUVjQwOGRJbGRPZnFMOGZJc3M1WVBDVEVQd1BoSl9Za1hJUXF4SUZhMy1JV0vSAeoBQVVfeXFMTXYyMXVKeURPSG1WTHBqZ0ZvejRRcnY1NkRiZFh0ZkZodXZhVWxFcEI4ZXl0YmZERnRZbkNhWDNxYmxwUV9EQXcwbnYxeERrd3J2RGVXbmxFVjJHazJ6YWM4QW5paVI1SklfcG05SlBfLTNpenNDb1haLV8yX05SUmtWbkFMUWE4Q2FnYWZyUmtoY3VrZUR0MTRac2VaNjJWNHdsQkpCRFBCSkFMV0RONVFLZUtSdW1MWEZKNmRUTFhlWlI0a0FaU2xqalNwRzZLRHdOZFh0TEx4MG1XaUJndGQwdzFYZl9tRjVn?oc=5","date":"2026-04-05","type":"pipeline","source":"simplywall.st","summary":"Why Tyra Biosciences (TYRA) Is Up 9.1% After $126 Million Block Sale And R&D Push - simplywall.st","headline":"Why Tyra Biosciences (TYRA) Is Up 9.1% After $126 Million Block Sale And R&D Push","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPWnltWUlONW1qWjVjbHNRZUpNeUhISjY5ZzNSRlAtR0pqMnRadHFGdi1KdTcwYlo2YXo2a1czdG5uMHFINDVBb1NwTFlCTUIxX0UxcmtkQ3pJSVA3YUFkaFdkbldpMUczaUpsNkdpLWM2M2hXcFZ1ZDl4dXl1NFU1RWQtelJHcS1GeS1DQjhpTnA0ZUYyc2VhVmV4MTZZR2F2RFJ3?oc=5","date":"2026-04-04","type":"trial","source":"Yahoo Finance","summary":"A Look At Tyra Biosciences (TYRA) Valuation After $126 Million Stock Sale And Late Stage Trial Progress - Yahoo Finance","headline":"A Look At Tyra Biosciences (TYRA) Valuation After $126 Million Stock Sale And Late Stage Trial Progress","sentiment":"neutral"},{"date":"2026-04-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gJBVV95cUxPdWpfRE9DNFBKQTFKRXZxU19sY0tFVnM0NGFfVjRTdkxSSDY5OW9fRzZEMjhMWEE2Vkp2S1dha3RjZU1xTVBhcENZbjE2aHRMTW5iU0tydFRKSUREWHBHRUwzWWxVTGQxRjAza1BJaktUTFNtaUE4allvLU14WU0ybWZSMm9zOXVEVnNWY1Y4ckFRajlUendLZU1LSUZFbTZ6VTRpN2ZNYkUzRHFLdlZWakZ2bjZiX18xRVIzYjNRNld5QmQ2cEdqYWswdHJCVzk3Y0s5YS1DYVZwbVlGb1NvMmpvUjNQamhhaEx1SGlGeXdyRUN0SlhvbkJjYkF2dTd4bTktWFZOalQtRTJiTVVOampJZmVNOEV2eG1MV1pXWEpYRlduMWpZSnFnVTVHSWE2TjV4YVhCN2JIX1Z1dkFTZVpqblA5endudkRoeHRDdTdzZw?oc=5","date":"2026-03-25","type":"pipeline","source":"Barchart","summary":"Non Muscle Invasive Bladder Cancer Pipeline Expands as 20+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | CG Oncology, Janssen, Tyra Biosciences, UroGen Pharma - B","headline":"Non Muscle Invasive Bladder Cancer Pipeline Expands as 20+ Pharma Companies Progress Novel Therapies Toward Market Entry","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-23","type":"pipeline","source":"simplywall.st","summary":"Assessing Tyra Biosciences (TYRA) Valuation After Strong One Year Share Price Performance - simplywall.st","headline":"Assessing Tyra Biosciences (TYRA) Valuation After Strong One Year Share Price Performance","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-21","type":"trial","source":"simplywall.st","summary":"Boone Capital Backs Tyra Biosciences As FGFR3 Trials Shape Outlook - simplywall.st","headline":"Boone Capital Backs Tyra Biosciences As FGFR3 Trials Shape Outlook","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxQNy1zbEVYRzBYemNxY1phZ0xWTGRnYUMtaEdpbUJUcFJITXlNeUNUWWUtckZfZnFFMHROYUhpSnlTVlNuRUJpaDkzU1BxUnBONHRsYXczeDhmcE9DNElYd3ZjQ2xxWkpmVXVLYmg4V0dRT3VmUkNjOXh1Y3Rpd2RheHUwelpKemhBYnlpM1lfbGpoeE14QTBacXY1Vzc0TUF1QldRSDVQVVhvRjhfdkhobFpKR3hPN2VLLUdzWWFWTGFiY2NyOUJ0Uk55bW1sdHJEOGRZY0paeUswbmNlNVBv?oc=5","date":"2026-03-20","type":"pipeline","source":"The Motley Fool","summary":"This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position - The Motley Fool","headline":"This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position","sentiment":"neutral"},{"date":"2026-03-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-02","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxOQVJvX05yVFBURmZrMzdzWUhjQ2xXRTFyLTFLMWtYV2FWbVJTMld0dm9MZXF2SDVzZm55QkFmWnA0ejEzQ19HcklyU0gtQmkzd2l4SU1EWEZoOXFrM2NTb0RKSEc0cHZkSlZyVzNVaE9Md1B0bEs0OG92LTRmX2gtMllhX0NQUHhYZmdXY1NTcW9jbC1KemwxRkRUSVhLRFVQRDNKendicjB3VHJhT3dGZjdxTTFoOWxnZEJtbW1XU2RFX2xOcml3dm4xel9YeFg1aFRFdDRHemFwaW9TLV9ib1NuN1JTYm15OEtDNi1JazNvdHFFMjJTZ2VDMGlXUlpsWTZUOUg3akFsenJuMl9UTV93TTlUUlBwUjRYNldrSnpTRnYzbnp0T2NocWJrYmVnME1j?oc=5","date":"2025-12-01","type":"regulatory","source":"PR Newswire","summary":"Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer - PR Newswire","headline":"Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather F","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-23","type":"pipeline","source":"simplywall.st","summary":"Insiders Who Sold US$628k Of Tyra Biosciences Made The Right Call - simplywall.st","headline":"Insiders Who Sold US$628k Of Tyra Biosciences Made The Right Call","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNcC1Nc3NGSXE1YVVVdnUtTWVkRjNsZWFubnlXakdBNTMxd2RSSmdZNU0tWDNHcTZObVFmZjBLVW0zVFlTMWZQLXdTd241NzB6M3hUYmNfTjBLaGdSbWtuaDl4WWFfUDBFRW1laW9pQzgyNU5KekJxNUNzZ1BJSW9ReFVwdXNVWms5MkRPSlExY0d4ZHZiejFrMms4c3ZrT2doSVNBdWhZckdjcWM?oc=5","date":"2025-08-22","type":"pipeline","source":"C&EN","summary":"Structures of 13 drug candidates unveiled at DC meeting - C&EN","headline":"Structures of 13 drug candidates unveiled at DC meeting - C&EN","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5ZSTNfSXNRNVpyT1BXaVkyb3dUeXdaUGN5ZjJmR01tcmxkVUY0WUtoOVd4LV9rLWNIdm9la294T0U3UXNlZHRzTlczekxVYzNXQmk0?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"Tyra Biosciences Stock Price, News & Analysis - Stock Titan","headline":"Tyra Biosciences Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxPc3RRb29DMktycmhqcUdLOGNUZ1JUdk1ia1VvSnR3QWJ3WWl4SUttUnhvME9uOXBsR3hSMWVrc1o0SEtFSmllb1M0N3pqUGFpMkEyX21UV2dkM1U5SDhid2Fxb3I5Sld6a0l2X21oVzFJMGRSVENkV1plRDlvLWN5SlR5eV9kY25LbXZlSVFDWkU4cWN6QVBIR3VxNTNOdFVUZmlCM0ZGYlFmM2NsQ0tIajJrUzM5U0dBX0xfamc4ZHRCbE9yejNQOHktQzI2QWI4REJMdG9SZnB1V240eWxaVA?oc=5","date":"2025-03-27","type":"earnings","source":"PR Newswire","summary":"Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights - PR Newswire","headline":"Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights","sentiment":"neutral"}],"patents":[{"drugName":"TYRA-100","drugSlug":"tyra-100","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0},{"drugName":"TYRA-200","drugSlug":"tyra-200","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Clovis Oncology","Foundation Medicine","Guardant Health"],"therapeuticFocus":["Precision Oncology","Cancer Treatment"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":102928000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-119947000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":77387000,"cashHistory":[],"totalAssets":282609000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}